查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1516329

癌症基因治療市場-按類型（體外、體內）、治療（溶瘤病毒療法、基因誘導免疫療法、基因轉移）、產品（病毒載體{腺病毒、慢病毒}、非病毒載體）、最終用途, 全球預測（2024 - 2032）

Cancer Gene Therapy Market - By Type (Ex-vivo, In-vivo), Therapy (Oncolytic Virotherapy, Gene-induced Immunotherapy, Gene Transfer), Product (Viral Vectors {Adenoviruses, Lentiviruses}, Non-viral Vectors), End-use, Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

由於全球癌症盛行率不斷增加，癌症基因治療市場規模預計在 2024 年至 2032 年間將以 20.5% 的複合年成長率擴大。基因工程和生物技術的巨大進步正在促進有效基因療法的開發。製藥公司和政府措施不斷增加的投資進一步支持研究和臨床試驗。

根據美國癌症協會的資料，預計2024年美國將新增2,001,140例癌症病例。人們越來越認知到基因療法在分子層面上針對癌症的潛力，這增加了其巨大的吸引力。遞送系統的創新發展和持續的臨床成功正在增強基因治療的可信度和興趣，從而促進市場成長。

整個產業分為類型、療法、產品、最終用途和地區。

根據類型，由於其高精度和有效性，到 2032 年，體外部分預計將在癌症基因治療市場中佔據相當大的佔有率。離體療法允許在體外修改患者細胞，以確保有針對性和受控的基因改變。細胞培養技術的進步和改進的輸送機制正在提高功效。臨床試驗成功率的不斷提高以及對個人化癌症治療的需求不斷成長正在加速該細分市場的成長。

就最終用途而言，由於癌症研究的資金和投資不斷增加，預計從 2024 年到 2032 年，研究機構領域的癌症基因治療產業規模將大幅成長。領先的研究機構專注於創新基因治療技術的開發、增進科學理解並進行臨床試驗。與製藥公司的合作和政府的支持也加速了這些療法在研究機構中的採用。

從地區來看，由於該地區癌症盛行率不斷上升以及人們對先進治療的認知不斷增強，預計亞太地區癌症基因治療產業將在 2024 年至 2032 年間取得實質進展。政府措施和資金的啟動正在支持基因治療的研發。生物技術和基因工程的進步正在提高治療效果。當地研究機構與全球製藥公司之間的創新合作將有利於區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 不斷增加的研發投資和對新型癌症療法的需求
      • 基因治療的技術進步
      • 癌症發生率增加
      • 產品核准和上市數量不斷增加
    • 產業陷阱與挑戰
      • 治療費用高
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 競爭定位矩陣
  • 戰略儀錶板

第 5 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 離體
  • 體內

第 6 章：市場估計與預測：按療法分類，2021 - 2032 年

  • 主要趨勢
  • 溶瘤病毒療法
  • 基因誘導的免疫治療
  • 基因轉移

第 7 章：市場估計與預測：按產品分類，2021 - 2032 年

  • 主要趨勢
  • 病毒載體
    • 腺病毒
    • 慢病毒
    • 逆轉錄病毒
    • 腺相關病毒
    • 單純皰疹病毒
    • 牛痘病毒
    • 其他病毒載體
  • 非病毒載體
  • 其他產品

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 生物製藥公司
  • 研究機構
  • 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要動向：按地區
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 亞太地區其他地區
  • 世界其他地區

第 10 章：公司簡介

  • Abeona Therapeutics Inc.
  • Altor Bioscience Inc.
  • Asklepios BioPharmaceutical Inc.
  • Bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Elevate Bio
  • Genelux Corporation
  • GlaxoSmithKline Inc.
  • Introgen Therapeutics Inc.
  • Merck KGaA
  • Novartis AG
簡介目錄
Product Code: 763

Cancer Gene Therapy Market size is projected to expand at 20.5% CAGR between 2024 and 2032, owing to the increasing prevalence of cancer worldwide. Strong advances in genetic engineering and biotechnology are facilitating the development of effective gene therapies. The growing investments from pharmaceutical companies and government initiatives are further supporting research and clinical trials.

According to data from the American Cancer Society, the U.S. is estimated to have 2,001,140 new cancer cases in 2024. The rising preference of patients for personalized medicine is driving the demand for gene therapy for cancer treatment. The growing awareness about the potential of gene therapy to target cancer at the molecular level is adding to its high appeal. Innovative developments in delivery systems and the ongoing clinical successes are bolstering the credibility and interest in gene therapy, adding to the market growth.

The overall industry is segregated into type, therapy, product, end-use, and region.

Based on type, the ex-vivo segment is projected to account for sizeable share of the cancer gene therapy market by 2032, owing to its high precision and effectiveness. Ex-vivo therapy allows the modification of patient cells outside the body for ensuring targeted and controlled genetic alterations. The advances in cell culture technologies and improved delivery mechanisms are improving efficacy. The increasing success rates in clinical trials and the growing demand for personalized cancer treatments are accelerating the segment growth.

In terms of end-use, the cancer gene therapy industry size from the research institutes segment is estimated to grow at significant rate from 2024 to 2032, due to the increasing funding and investments in cancer research. Leading research institutes are focusing on the development of innovative gene therapy techniques, advancing scientific understanding, and conducting clinical trials. The collaboration with pharmaceutical companies and government support are also accelerating the adoption of these therapies in research institutes.

Regionally, the Asia Pacific cancer gene therapy industry is projected to depict substantial gains between 2024 and 2032, on account of the rising cancer prevalence and increasing awareness of advanced treatments in the region. The launch of government initiatives and funding are supporting R&D in gene therapy. The advances in biotechnology and genetic engineering are enhancing treatment efficacy. The collaborations between local research institutes and global pharmaceutical companies for innovations will favor the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising R&D investments and demand for novel cancer therapeutics
      • 3.2.1.2 Technological advancements in gene therapy
      • 3.2.1.3 Increasing incidence of cancer
      • 3.2.1.4 Increasing number of product approvals and launches
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of therapy
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Ex-vivo
  • 5.3 In-vivo

Chapter 6 Market Estimates and Forecast, By Therapy, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Oncolytic virotherapy
  • 6.3 Gene-induced immunotherapy
  • 6.4 Gene transfer

Chapter 7 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Viral vectors
    • 7.2.1 Adenoviruses
    • 7.2.2 Lentiviruses
    • 7.2.3 Retrovirus
    • 7.2.4 Adeno associated virus
    • 7.2.5 Herpes simplex virus
    • 7.2.6 Vaccinia virus
    • 7.2.7 Other viral vectors
  • 7.3 Non-viral vectors
  • 7.4 Other products

Chapter 8 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Million)

  • 8.1 Key trends
  • 8.2 Biopharma companies
  • 8.3 Research institutes
  • 8.4 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

  • 9.1 Key trends, by region
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 Rest of Asia Pacific
  • 9.5 Rest of the World

Chapter 10 Company Profiles

  • 10.1 Abeona Therapeutics Inc.
  • 10.2 Altor Bioscience Inc.
  • 10.3 Asklepios BioPharmaceutical Inc.
  • 10.4 Bluebird bio, Inc.
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Elevate Bio
  • 10.7 Genelux Corporation
  • 10.8 GlaxoSmithKline Inc.
  • 10.9 Introgen Therapeutics Inc.
  • 10.10 Merck KGaA
  • 10.11 Novartis AG